Retatrutide FDA Approval Timeline: When Will It Be Available?

Short answer: retatrutide is not approved anywhere and has not yet been submitted to the FDA. Eli Lilly plans to submit in the first quarter of 2027. If it does, and the FDA uses its standard timeline, a decision would come around the first quarter of 2028; with priority review, around late 2027. These dates are our calculation from the FDA’s published review goals, not a Lilly forecast. Two new factors could move them: the FDA’s October 2026 ruling that retatrutide must be filed as a drug rather than a biologic, and the possibility of a national priority voucher, which can shorten review to a few months.

Where retatrutide stands (October 2026)

• Not approved by the FDA or any other regulator, for any condition.
• Not yet submitted. Lilly said on August 5, 2026 that “the clinical data package is now complete to support global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain,” with plans to submit “in the first quarter of 2027.” It repeated the Q1 2027 plan on September 29, 2026.
• All pivotal obesity trials have reported, and the main results are now peer-reviewed:
  • TRIUMPH-4 (obesity with knee osteoarthritis), reported December 2025.
  • TRIUMPH-1 (obesity), New England Journal of Medicine, September 29, 2026: 25.0% weight loss at 12 mg over 80 weeks (28.3% in Lilly’s efficacy analysis).
  • TRIUMPH-2 (obesity with type 2 diabetes), The Lancet, September 29, 2026: 18.8% at 12 mg (20.8% efficacy analysis).
  • TRIUMPH-3 (severe obesity with cardiovascular disease), reported July 2026.
  • Sleep apnea results from TRIUMPH-1 and TRIUMPH-2, NEJM, October 20, 2026.
• The FDA has classified retatrutide as a drug (October 2, 2026), which means an application under section 505 of the Food, Drug, and Cosmetic Act (an NDA). Lilly’s public statements, all made before that letter, refer to a Biologics License Application (BLA). Lilly is contesting the classification. Details in FDA Says Retatrutide Is a Drug, Not a Biologic.

A plain-language summary of the published trials is in Retatrutide’s Published Trials, Explained.

How long FDA review takes

Under the FDA’s user-fee commitments (PDUFA VII), the agency aims to act on a new molecular entity NDA or an original BLA:

The goals are the same for an NDA and a BLA, and the FDA says the same center (CDER) will review retatrutide either way. A major amendment during review can add three months.

National priority voucher. The FDA runs a Commissioner’s National Priority Voucher program; in its words, the “target timeline for decisions under the program is two months.” Lilly’s orforglipron (Foundayo) was approved under it on April 1, 2026, “50 days after filing.” We have found no public report that retatrutide has received a voucher. If it did, a decision could come within a few months of submission rather than a year.

Realistic timelines

These scenarios assume Lilly submits in the first quarter of 2027, as it has said.

After approval, launch and pharmacy availability usually follow within weeks to a few months, and insurance coverage can take longer.

Does the FDA’s “drug, not biologic” ruling delay approval?

Probably not directly. The review clock and the reviewing center are the same either way. It could cause a delay only if Lilly had to restructure its application, or chose to wait for the courts. The Seventh Circuit heard Lilly’s appeal on September 24, 2026 and, as of October 31, had not ruled. The classification mainly affects what happens after approval: how long retatrutide is protected from copies, and whether compounding could ever be lawful.

Lilly’s third-quarter results on October 29, 2026 did not mention a filing date or pathway. Its most recent statement, in an October 8 court filing, is that it plans to file “no later than the first quarter of 2027”.

How this compares with Lilly’s last obesity drugs

A key difference: tirzepatide was already approved for type 2 diabetes (as Mounjaro) before its obesity approval. Retatrutide would be a new molecule with no prior approval, so the FDA will assess its full safety database, including the dysesthesia and heart-rate findings, for the first time.

Europe and elsewhere

We have found no submission to the European Medicines Agency. The EMA’s standard assessment takes up to 210 days of active review, not counting the time companies take to answer questions, so European approval would follow a US decision by months at least. See retatrutide in the UK and Europe.

What still has to happen

1. Pivotal trials report Done.
2. Main results peer-reviewed Done for TRIUMPH-1, TRIUMPH-2 and the sleep apnea trials.
3. Application submitted (planned Q1 2027), as an NDA or BLA depending on the classification dispute.
4. FDA accepts it for review (within 60 days).
5. FDA review, possibly with an advisory committee meeting.
6. Decision and labeling.
7. Commercial supply and launch.

How to get retatrutide before approval

Only through a clinical trial or, for adults with severe obesity that has not responded to approved treatments, through a physician request to Lilly’s expanded access program. Our trial finder lists studies that are recruiting. Products sold online as retatrutide are unapproved and have been found to contain the wrong drug or none; see Black-Market Retatrutide: Reported Deaths and Real Dangers.

Frequently asked questions

When will retatrutide be approved?

If Lilly submits in the first quarter of 2027 as planned, a standard FDA review points to a decision around the first quarter of 2028, and priority review to late 2027. A national priority voucher, if granted, could bring it forward to 2027. No date is guaranteed.

Has Lilly filed for approval?

No. As of October 31, 2026, Lilly says it plans to file no later than the first quarter of 2027.

Will the FDA’s ruling that retatrutide is a drug delay it?

Not by itself, as far as is publicly known. Review timelines are the same for a drug application and a biologics application. Lilly has not said whether its filing plans have changed.

When will retatrutide be available in pharmacies?

Not before approval. After approval, launch typically follows within weeks to a few months, depending on manufacturing supply.

This page is for education and is not medical or legal advice. Timelines are estimates based on public information and can change.